Most of the 17 products are targeted oncology drugs, and all of them are oncology or rare disease drugs with huge clinical demands. Most of them have been rapidly marketed through priority review or "two-application two-approval" policy, and after they are included in the medical insurance payment, payment pressure of patients will be further reduced.
According to statistical data, the 17 drugs have been reduced prices by 27%-74% after succeeding in the medical insurance access negotiations, wherein, Zykadia (ceritinib) will be reduced price by up to 74%. Refer to the attached table for the detailed prices.
II. Anticancer Drugs to be Further Reduced Prices after being Included in the Medical Insurance: A Comparison of Their Prices in China and outside China
|
赞可达
泰瑞沙
英立达
赛可瑞
达希纳
爱必妥
维全特
亿珂
索坦
维达莎
佐博伏
恩莱瑞
拜万戈
福可维
吉泰瑞
善龙
艾阳
|
Zykadia
Tagrisso
Inlyta
Xalkori
Tasigna
Erbitux
Votrient
Imbruvica
Sutent
Vidaza
Zelboraf
Ninlaro
Stivarga
FOCUS V
Gilotrif
Sandostatin LAR
Aiyang
|
|
中标价格（元）
医保谈判（元）
|
Bid winning price (RMB)
Medical insurance negotiation price (RMB)
|
I have obtained prices of the 17 drugs in China and outside China according to public data, with prices in China subject to bid winning prices in provinces of China and overseas prices subject to those in the U.S.
Bid winning prices in China are generally 30%-50% of prices of same specifications in the U.S. The drug prices will be further reduced after success of the medical insurance access negotiations, as proved by that the fact that the medical insurance negotiation prices are 47%-96% lower than the U.S. prices, which will significantly reduce payment pressure of patients. Refer to the following table for the details:
|
Trade name
|
Specification
|
U.S.
(RMB)
|
Bid winning price
(RMB)
|
Medical insurance price
(RMB)
|
Reduction of medical insurance negotiation price vs bid winning price
|
Reduction of medical insurance negotiation price vs U.S. price
|
|
Zykadia
|
150mg
|
749
|
749.00
|
198
|
74%
|
74%
|
|
Tagrisso
|
80mg
|
3,382
|
1,760.00
|
510
|
71%
|
85%
|
|
Inlyta
|
5mg
|
1,645
|
686.85
|
207
|
70%
|
87%
|
|
Xalkori
|
250mg
|
1,816
|
858.25
|
260
|
70%
|
86%
|
|
Tasigna
|
150mg
|
1,929
|
237.43
|
76
|
68%
|
96%
|
|
Erbitux
|
100 mg
20 mL
|
|
3,826.65
|
1,295
|
66%
|
|
|
Votrient
|
200mg
|
692
|
457.50
|
160
|
65%
|
77%
|
|
Imbruvica
|
140mg
|
930
|
540.00
|
189
|
65%
|
80%
|
|
Sutent
|
12.5mg
|
1,191
|
432.09
|
155
|
64%
|
87%
|
|
Vidaza
|
100mg
|
4,990
|
2,625.00
|
1,055
|
60%
|
79%
|
|
Zelboraf
|
240mg
|
210
|
210.00
|
112
|
47%
|
47%
|
|
Ninlaro
|
4mg
|
22,473
|
9,200.00
|
4,933
|
46%
|
78%
|
|
Stivarga
|
40mg
|
1,374
|
360.00
|
196
|
46%
|
86%
|
|
FOCUS V
|
12mg
|
|
885.71
|
487
|
45%
|
|
|
Gilotrif
|
40mg
|
1,890
|
324.96
|
200
|
38%
|
89%
|
|
Sandostatin LAR
|
30mg
|
57,546
|
11,006.54
|
7,911
|
28%
|
86%
|
|
Aiyang
|
5ml 3750 IU
|
|
4,072.94
|
2,980
|
27%
|
|
Attached table: Prices of 17 Oncology Drugs in China and outside China
|
Marketing time in China
|
Trade name
|
Generic name
|
Price after negotiation
|
Bid winning price
(RMB/1 specification)
|
U.S. price
(RMB/1 specification)
|
|
2015
|
Inlyta
|
Axitinib
|
5 mg, RMB 207
1 mg, RMB 60.4
|
5 mg, RMB 704
1 mg, RMB 200
|
5 mg, RMB 1,645
1 mg, RMB 567
|
|
2017
|
Tagrisso
|
Osimertinib
|
80 mg, RMB 510
40 mg, RMB 300
|
80 mg, RMB 1,760
|
80 mg, RMB 3,382
|
|
2018
|
Ninlaro
|
Ixazomib
|
4 mg, RMB 4,933
3 mg, RMB 3,957.9
2.3 mg, RMB 3,229.4
|
4 mg, RMB 9,200
3 mg, RMB 7,381
|
4 mg, RMB 22,473
|
|
2013
|
Xalkori
|
Crizotinib
|
250 mg, RMB 260
200 mg, RMB 219.2
|
250 mg, RMB 890
200 mg, RMB 749
|
250 mg, RMB 1,816
200 mg, RMB 1,800
|
|
2017
|
Jakavi
|
Ruxolitinib
|
Failed negotiation
|
5 mg, N/A
|
5 mg, RMB 1,396
|
|
2017
|
Gilotrif
|
Afatinib
|
40 mg, RMB 200
30 mg, RMB 160.5
|
40 mg, RMB 328
30 mg, RMB 264
|
40 mg, RMB 1,890
30 mg, RMB 1,861
|
|
2009
|
Tasigna
|
Nilotinib
|
200 mg, RMB 84.7
150 mg, RMB 76
|
200 mg, RMB 304
150 mg, RMB 241
|
150 mg, RMB 1,929
|
|
2009
|
Aiyang
|
Pegaspargase
|
5ml:3750IU, RMB 2,980
2ml:1500IU, RMB 1,477.7
|
5ml:3750IU, RMB 4,073
|
N/A
|
|
2017
|
Votrient
|
Pazopanib
|
400 mg, RMB 272
200 mg, RMB 160
|
200 mg, RMB 457
|
200 mg, RMB 692
|
|
2007
|
Sutent
|
Sunitinib
|
50mg, RMB 448
37.5 mg, RMB 359.4
12.5 mg, RMB 263.5
12.5 mg, RMB 155
|
12.5 mg, RMB 454
|
12.5 mg, RMB 1,191
|
|
2017
|
Stivarga
|
Regorafenib
|
40 mg, RMB 196
|
40 mg, RMB 360
|
40 mg, RMB 1,374
|
|
2018
|
Zykadia
|
Ceritinib
|
150 mg, RMB 198
|
150 mg, RMB 749
|
150 mg, RMB 749
|
|
2017
|
Zelboraf
|
Vemurafenib
|
40 mg, RMB 112
|
240 mg, RMB 210
|
240 mg, RMB 210
|
|
2006
|
Erbitux
|
Cetuximab
|
100mg(20ml), RMB 1,295
|
100mg/20ml, RMB 3,827
|
100mg/20ml, N/A
|
|
2018
|
FOCUS V
|
Anlotinib
|
12 mg, RMB 487
120mg, RMB 423.6
8mg, RMB 357
|
12 mg, RMB 885
|
N/A
|
|
2017
|
Imbruvica
|
Ibrutinib
|
140 mg, RMB 189
|
140 mg, RMB 540
|
140 mg, RMB 930
|
|
2018
|
Vidaza
|
Azacitidine
|
100 mg, RMB 1,055
|
100 mg, RMB 2,625
|
100 mg, RMB 4,990
|
|
2013
|
Sandostatin LAR
|
Octreotide microspheres
|
30 mg, RMB 7,911
20 mg, RMB 5,800
|
30 mg, RMB 13,100
20 mg, RMB 9,600
|
30 mg, RMB 57,546
20 mg, RMB 50,033
|
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight JANUARY 2024
